Amgen’s Weight Loss/Diabetes Drug MariTide Shows Promise, But Analyst Raises Questions - Amgen (NASDAQ:AMGN)

Breakthrough T1D Joins Diabetes Leaders at the American Diabetes Association 85th Scientific Sessions to Highlight Research Advancements

NEW YORK, June 24, 2025 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the American Diabetes Association's (ADA) 85th Scientific…

Amgen’s Weight Loss/Diabetes Drug MariTide Shows Promise, But Analyst Raises Questions - Amgen (NASDAQ:AMGN)

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Obesity on the agenda - slimming down the European way

"If we lose up to 15% of our weight, that can lead to a 61% remission in cases of type 2 diabetes."

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks